Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services... see more

OTCPK:MEDVF - Post Discussion

Medivolve Inc > Following honest webinar: MEDV - upgraded to a BUY
View:
Post by Hiddensecrets on Mar 23, 2021 3:05pm

Following honest webinar: MEDV - upgraded to a BUY

I spoke to my banker and i was informed that the selloff is over.

They attended the webinar and it was a toned down version of reality with expectations of cubes being drastically cut down and kept at 48 for the remainder of the year, down from the hyped level of 2,000 cubes.

The company has also showed a willingness to pivot away from poor cubes sales.

Reasonable expectation of revenue put at $ 35 million per year USD.


CATALYSTs      Nutrcell orders pending with several institutions

                         Awaiting confirmation of govnt contracts on vaccination in California - $ 40 per shot.

                         Blowfish technology 2 month testing completed in May 2021 - then to FDA for approval

I hope my banker is right.

MPO
Comment by Randy33 on Mar 23, 2021 3:07pm
Thank you for the advise. I justloaded up with 0.20 cents. Thank you sir.
Comment by knowsbest on Mar 23, 2021 3:10pm
I told you these are good meds .I got similar message . Did he mentioned the big guy ?
Comment by Catspajamas on Mar 23, 2021 6:48pm
and I thought Donald Trump was the most ridiculous person I've ever seen but with yet another flip flop, it's definitely you
Comment by knowszero on Mar 23, 2021 8:38pm
I'm quite disappointed in the Gen X and Gen Y posters on here mostly. They are like a pack of hyenas on here. What an embarrassment. Thats why I don't even come on here any more. We call the millennials entitled, that's completely wrong. They band together, share there gains and support each other. Hiddensecret, Knowsbest and a few others really take a real good look at themselves.
Comment by Jasper66 on Mar 23, 2021 9:03pm
Completely agree. Bought both gme and amc to support the Apes. Been holding whether it go's up or down. As I read the stories of other Apes who would benefit, I keep on buying more. People on here have lost there moral compass. Nice example were setting for our kids. Only care about yourself and the rest can fu(k themselves.
Comment by maidenmist on Mar 23, 2021 9:13pm
WHAT institutional firm said outtright that this stock was a buy? And what banker from previous posts said this was a buy? Because the way things are going with this stock (and I'm still bleedign red, til financials come out), all of us have yet to see a bottom and said banker should shave his license reviewed. Still holding for the record TILL end of April.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities